TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Ascletis Pharma, Inc. ( (HK:1672) ).
Ascletis Pharma, Inc. announced the completion of a placing and subscription of shares, raising approximately HK$467.69 million in net proceeds. The funds are primarily earmarked for advancing the company’s drug candidates into clinical trials for obesity, with a small portion allocated for general corporate purposes. This strategic move is expected to bolster Ascletis Pharma’s R&D capabilities and strengthen its market position.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$14.75 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
More about Ascletis Pharma, Inc.
Ascletis Pharma, Inc. is a pharmaceutical company incorporated in the Cayman Islands, focusing on the research and development of innovative drug candidates. It specializes in subcutaneously injected peptides and oral peptides, targeting clinical trials for conditions such as obesity.
Average Trading Volume: 8,067,555
Technical Sentiment Signal: Buy
Current Market Cap: HK$14.4B
Find detailed analytics on 1672 stock on TipRanks’ Stock Analysis page.